Prenatal Tdap immunization and risk of maternal and newborn adverse events

Many countries recommend combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis immunization (Tdap) during pregnancy to stimulate transplacental transmission of pertussis antibodies to newborns. The immune system can be altered during pregnancy, potentially resulting in differing...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2017-07, Vol.35 (33), p.4072-4078
Main Authors: Layton, J. Bradley, Butler, Anne M., Li, Dongmei, Boggess, Kim A., Weber, David J., McGrath, Leah J., Becker-Dreps, Sylvia
Format: Article
Language:English
Subjects:
Adult
Age
Algorithms
Anaphylaxis
Antibodies
Birth
Chorioamnionitis
Codes
Cohort Studies
Diabetes
Diphtheria
Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage
Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects
Disease control
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - pathology
Eclampsia
Encephalopathy
Epidemiology
Female
Fever
Guillain-Barre syndrome
Hazards
Health care
Hemorrhage
Humans
Hypertension
Immune system
Immunization
Infant, Newborn
Influenza
Insurance claims
Jaundice
Membranes
Mother-child linkage
Neonates
Optimization
Pertussis
Pharmacoepidemiology
Postpartum
Pre-eclampsia
Pregnancy
Pregnancy Outcome
Prenatal Care - methods
Product safety
Regression analysis
Risk Assessment
Rupture
Rupturing
Safety
Stillbirth
Tdap
Tetanus
Vaccines
Whooping cough
Womens health
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many countries recommend combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis immunization (Tdap) during pregnancy to stimulate transplacental transmission of pertussis antibodies to newborns. The immune system can be altered during pregnancy, potentially resulting in differing immunization risks in pregnant women. The safety of widespread Tdap immunization during pregnancy needs to be established. Our objective was to assess whether prenatal Tdap immunization was associated with adverse birth outcomes, and to evaluate the effect of timing of Tdap administration on these outcomes. We identified pregnancies at delivery in a large insurance claims database (2010–2014). Tdap immunization was categorized as optimal prenatal (27+weeks), early prenatal (
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2017.06.071